tbuckley/cabot-search huggingface dataset:
重要なウイルス成分の細胞内自己集合に基づく多標識:エンベロープ,カプシドと核酸【Powered by NICT】
Authors: Wen Li, Lin Yi, Zhang Zhi-Ling, Lu Wen, Lv Cheng, Chen Zhi-Liang, Wang Han-Zhong, Pang Dai-Wen
Journal: Biomaterials (2016)
ICDを有する器質的心疾患患者の予後はマイクロボルトレベルのT波交互脈(TWA)と関係していた
Authors: Tanno Kaoru, Onuki Tatsuya, Miyoshi Fumito, Minoura Yoshino, Kawamura Mitsuharu, Asano Taku, Kobayashi Youichi
Journal: Circulation (2008)
AB0327 Fear of falling and foot pain, impairment and disability in rheumatoid arthritis
Authors: J Bahha, B Amine, M Erraoui, Y Boujenane, S Fellous, I El Binoune, R Bahiri
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Fear of falling, foot pain and functional disability are commonly reported in rheumatoid arthritis. Moreover, the relationship between the fear of falling and foot pain, impairment and disability has rarely been studied. <h3>Objectives</h3> To evaluate the relationship between fear of falling and foot pain, impairment and disability in patients with established RA. <h3>Methods</h3> A cross-sectional study that included patients with rheumatoid arthritis. We collected the following data: age, sex, duration of disease, foot pain assessed by the Visual Analogue Scale (VAS), Disease activity assessed by DAS 28, HAQ disability index (HAQ-DI). Fear of falling was assessed by Falls Efficacy Scale-International (FES-I) which consists of 16 different activities, scored using a four point scale (1=not at all concerned, 2=somewhat concerned, 3=fairly concerned and 4=very concerned). The summed scores for the 16 activities for each participant were calculated. Scores of ≥23 indicated a significant fear of falling. Foot disability and impairment were measured using the Leeds Foot Impact Scale (LFIS), Foot disability was represented by the total score (LFIST; range 0 to 51) of the LFIS and foot impairment by the first subscale (LFISIF; range 0 to 21). Correlations were used to assess the relationship between fear of falling and foot pain, impairment and disability. <h3>Results</h3> Thirty-three patients were included. The mean age was 49.3±10.5 years with female predominance (n=29 (87.9%)). The mean disease duration was 9.9±7.5 years. The mean HAQ-DI was 1.3±0.8. The mean DAS28 score was 5.5±1.3 and the mean EVA foot pain was 5.5±2.4. The mean FES-I score was 37.4±15.1 and 69.7% (n=23) of patients had a significant fear of falling. Positive correlations were found between fear of falling and foot impairment (r=0.66; p&lt;0.0001) and disability (r=0.80; p&lt;0.0001). No correlation was found between fear of falling and foot pain (r =0.29, p=0.07). <h3>Conclusions</h3> The results of this study have demonstrated the importance of the relationship between fear of falling and foot impairment and disability. <h3>Disclosure of Interest</h3> None declared
O<sup>6</sup>-benzylguanine (BG) and temozolomide (TMZ) therapy of glioblastoma multiforme (GBM) with infusion of autologous lentiviral transduced P140KMGMT+ hematopoietic progenitors to protect hematopoiesis: A phase I study.
Authors: Andrew E. Sloan, Jane Reese, Lisa R. Rogers, Simon S. Lo, Charles John Nock, Hillard M. Lazarus, Mitchell Machtay, PingFu Fu, Hua Fung, Heather Embree, Boro Dropulic, Stanton Gerson
Journal: Journal of Clinical Oncology (2012)

TPS1616 Background: The administration of radiation therapy (RT) and concomitant and adjuvant temozolomide (TMZ) for the treatment of newly-diagnosed glioblastoma (GBM) is associated with modestly prolonged survival. However, the benefit of concurrent therapy is restricted to a subgroup of patients whose tumor exhibits methylation of the promoter for methylguanine-DNA-methyltransferase (MGMT). Promoter methylation silences the expression of DNA alkyltransferase (AGT), the product of the MGMT gene which functions to repair alkylated DNA. Unfortunately, the majority of GBMs have non-methylated MGMT promoters and do not appear to benefit from adding TMZ to radiotherapy. Two potential strategies for targeting MGMT-induced chemoprotection in gliomas include depletion of tumor MGMT, and dose escalation of TMZ accomplished by minimizing TMZ-induced bone marrow toxicity. In this study, we propose to combine the irreversible MGMT inhibitor O6-benzylguanine (BG) with infusion of autologous hematopoetic stem cells (HSCs) transduced with lentiviral P140K-MGMT, an MGMT mutant which is highly resistant to inactivation by BG, with the intent to reduce or prevent the myelosuppressive effects of TMZ. The primary objective is to assess the safety and feasibility of combining these two strategies in patients with newly-diagnosed GBM. Methods: This is a three cohort, Phase I study for patients with newly resected supratentorial GBM. There will be at least four evaluable patients per cohort. Cohort 1 will receive standard RT and concomitant TMZ prior to infusion of autologous lentiviral P140K-MGMT transduced HSCs, followed by adjuvant TMZ. Cohort 2 will receive an induction dose of TMZ+BG followed by infusion of autologous LV-P140K-MGMT HSCs prior to concomitant RT +TMZ and adjuvant TMZ. Cohort 3 will include intra-patient dose escalation of TMZ in patients who exhibit detectable levels of P140K-MGMT marked cells in vivo, using the design (i.e. cohort 1 or 2) proven to be safest and most effective. The study is open and has accrued the first patient.
The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events
Authors: Alexander Egeberg, Lone Skov, Aditya A. Joshi, Lotus Mallbris, Gunnar H. Gislason, Jashin J. Wu, Justin Rodante, Joseph B. Lerman, Mark A. Ahlman, Joel M. Gelfand, Nehal N. Mehta
Journal: Journal of the American Academy of Dermatology (2017)
免疫性血小板減少症の治療のための抗体デコイとしての血小板膜コーティングのカモフラージュナノ粒子【Powered by NICT】
Authors: Wei Xiaoli, Gao Jie, H Fang Ronnie, T Luk Brian, V Kroll Ashley, Dehaini Diana, Zhou Jiarong, Kim Hyeon Woo, Gao Weiwei, Lu Weiyue, Zhang Liangfang
Journal: Biomaterials (2016)
インテグリンα_vβ_3オステオポンチン界面を標的とする新規小分子PPI阻害剤はin vitroでの骨吸収を阻害し,マウスにおける骨量減少を予防する【Powered by NICT】
Authors: Park Doori, Park Chan-Won, Choi YoungJin, Lin Jingjing, Seo Dong-Hyun, Kim Han-Sung, Lee Soo Young, Kang In-Cheol
Journal: Biomaterials (2016)
Production of Gastric Lesions in Rats by Fasting, Partial Inanition, and Deficiency of Certain Dietary Constituents
Authors: Harold P. Morris, Stuart W. Lippincott
Journal: JNCI Journal of the National Cancer Institute (1942)

Journal Article Production of Gastric Lesions in Rats by Fasting, Partial Inanition, and Deficiency of Certain Dietary Constituents Get access Harold P. Morris, Harold P. Morris senior nutrition chemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Stuart W. Lippincott Stuart W. Lippincott passed assistant surgeon National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 5, April 1942, Pages 459–477, https://doi.org/10.1093/jnci/2.5.459 Published: 01 April 1942
Morphine-induced angiogenesis is blocked by methylnaltrexone
Authors: Jonathan Moss, Mary Jo Fekete, Mark Lingen
Journal: Cancer Research (2006)

965   Introduction: Although morphine (MS) is widely used in patients with advanced cancer, prior in vitro studies have demonstrated that MS, in clinically relevant doses, promotes neovascularization in human breast cancer xenografts. 1  However, the opiate antagonist naloxone (N) did not inhibit the proangiogenic activity of MS. We utilized a modified chemotaxis assay 2  to quantitatively assess whether clinically relevant doses of MS stimulate or inhibit endothelial cell migration, and to assess whether this activity could be blocked by N and methylnaltrexone (MNTX), a peripheral opiate antagonist in Phase 3 clinical trials for opiate induced constipation in advanced medical illness. 3  We further wished to assess the concentration of MNTX required to attenuate MS at a therapeutically relevant concentration (10 -7 M). Methods:: The endothelial cell migration assay was performed as previously described. 2  Human dermal microvascular endothelial cells (Cell Systems, Kirkland, WA) were starved overnight in media containing 0.1% bovine serum albumin (BSA), harvested, resuspended into DME with 0.1% BSA, and plated on a semi-porous gelatinized membrane in a modified Boyden chamber (Nucleopore Corporation, MD). Test substances were then added to the wells of the upper chamber and cells were allowed to migrate for four hours at 37° C. Membranes were recovered, fixed, and stained and the number of cells that had migrated to the upper chamber per ten high power fields counted by a blinded observer. Background migration to DME + 0.1% BSA was subtracted and the data reported as the number of cells migrated per 10 high power fields (400x). Each substance was tested in quadruplicate in each experiment and all experiments were repeated at least twice. VEGF (RD 62:4491-8. 2. Methods Mol Med 2003; 78:337-47. 3. ASA Refresher Courses in Anesthesiology Vol. 33, 2005, pp. 175-186 (in press)
Has health-related quality-of-life assessment in EORTC clinical trials helped to obtain regulatory approvals and change clinical practice? A review of the EORTC experience in cancer clinical trials.
Authors: Efstathios Zikos, Corneel Coens, Miriam Sprangers, Eva Greimel, Irina Ghislain, Divine Ewane Ediebah, Henning Flechtner, Andrew Bottomley
Journal: Journal of Clinical Oncology (2014)

9570 Background: Health-related quality of life (HRQOL) has been an important part of the randomised controlled trials (RCTs) conducted by EORTC since 1980. This review aims to provide an update on a previous descriptive evaluation of EORTC RCTs from 2002 and select those whose HRQOL results changed clinical practice and helped to obtain regulatory approvals. Methods: The EORTC database was reviewed, restricting the search to the period 2002–2013. The published review from 1980–2001, involving over 65,000 patients, was also taken into consideration. We investigated the number of EORTC RCTs including HRQOL and identified those that altered clinical practice and influenced label claims. Results: 52 RCTs with HRQOL assessment were identified, involving 37,417 patients. The majority of phase II and III RCTs (n=45) have HRQOL as secondary endpoint. EORTC also conducted supportive care and translational research trials with an HRQOL component. The EORTC clinical groups with the most RCTs containing HRQOL were Radiation Oncology (17%, n=9) and Brain Tumour (13%, n=7). As examples of practice-changing RCTs, EORTC 22952-26001 found whole-brain radiotherapy not to improve OS while affecting HRQOL adversely (global health status (GHS), physical/cognitive functioning, and fatigue). EORTC 62072 in patients with advanced soft-tissue sarcoma, following chemotherapy treatment, found that pazopanib toxicity did not translate into significantly worse HRQOL (GHS: P=0.291; average difference=2.6 points) and nearly tripled PFS (HR 0.31; p<0.0001). RCTs whose HRQOL component helped to obtain regulatory approvals were EORTC 18991, 26981, and 62072. Conclusions: Our review shows how patient perspective in palliative and curative trials has been considered of major importance in oncology and demonstrates how recent findings in EORTC RCTs have altered clinical practice, providing recommendations for future improvements and helping label claims. The inclusion of patient perspective in drug development shows that a more comprehensive HRQOL assessment has taken place over time as better instruments have become available.
AB0065 Side effects of depot corticosteroid – diprophos® in the long term treatment of rheumatoid arthritis
Authors: DZ Stefanovic, BC Glisic, ZV Andjelkovic, MM Cirkovic, MR Petronijevic, DV Mitrovic, MM Popovic
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Corticosteroids are widely prescribed as potent anti-inflammatory drugs, but in treatment of rheumatoid arthritis (RA) severe adverse effects often limit their benefits. <h3>Objectives</h3> We estimated side effects of depot corticosteroid – diprophos® in the long term treatment of rheumatoid arthritis. <h3>Methods</h3> During six years we followed up 185 patients from the first onset of RA. Among them, 47 have been treated with combined therapy with methotrexate and chlorochine, 36 with methotrexate and sulfasalazine, while 38, 41 and 23 were on monotherapy with methotrexate, chlorochine and sulfasalazine, respectively. In all these patients, depot corticosteroid DIPROPHOS® (betametazone – combined sodium dipropionate/phosphate salt) have been administrated in 3‑5 weeks periodic intervals as one i.m. injection during minimum 6 months. <h3>Results</h3> In most of patients (168/185 i.e. 91%) permanent clinical and biohumoral remission with slow radiographic disease progression was obtained. At the same time, we failed to notice any metabolic and gastrointestinal side effects due to corticosteroid use. Also in long-time follow up, there was no evidence of clinically important hormonal and psychiatric impairments as well as frequent infections. Only skin and ocular adverse effects were noticed. <h3>Conclusion</h3> Depot corticosteroids could be considered as integral effective and safe part of RA treatment.
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor
Authors: Samantha Gadd, Vicki Huff, Amy L Walz, Ariadne H A G Ooms, Amy E Armstrong, Daniela S Gerhard, Malcolm A Smith, Jaime M Guidry Auvil, Daoud Meerzaman, Qing-Rong Chen, Chih Hao Hsu, Chunhua Yan, Cu Nguyen, Ying Hu, Leandro C Hermida, Tanja Davidsen, Patee Gesuwan, Yussanne Ma, Zusheng Zong, Andrew J Mungall, Richard A Moore, Marco A Marra, Jeffrey S Dome, Charles G Mullighan, Jing Ma, David A Wheeler, Oliver A Hampton, Nicole Ross, Julie M Gastier-Foster, Stefan T Arold, Elizabeth J Perlman
Journal: Nature Genetics (2017)
RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic <i>BRCA</i> mutation.
Authors: Susan M. Domchek, Andrew Eugene Hendifar, Robert R. McWilliams, Ravit Geva, Ron Epelbaum, Andrew Biankin, Robert H. Vonderheide, Robert A. Wolff, Steven R. Alberts, Heidi Giordano, Sandra Goble, Kevin K. Lin, Rachna T. Shroff
Journal: Journal of Clinical Oncology (2016)

4110 Background: Pts with PC have a poor prognosis and limited treatment options. Around 9% of pts with PC have a germline or somatic BRCA mutation. Recent studies showed that rucaparib effectively treats pts with platinum-sensitive, relapsed, high-grade ovarian carcinoma and a BRCA mutation. RUCAPANC investigated the efficacy and safety of rucaparib in pts with PC and a known deleterious BRCA mutation. Methods: RUCAPANC (NCT02042378) enrolled pts with PC with measurable, relapsed disease who received 1–2 prior chemotherapy regimens in the locally advanced/metastatic setting. Pts received oral rucaparib (600 mg twice daily) until disease progression. The primary endpoint was objective response rate (ORR) by RECIST v1.1. Safety was also evaluated. Results: Nineteen pts were treated; 3 pts are ongoing. Median age was 57 years (range 41–75), 58% were male, 68% received ≥ 2 prior chemotherapy regimens (including adjuvant treatment), 79% were ECOG Performance Status of 1, and 79% had a BRCA2mutation by local testing. The confirmed ORR was 11% (1 partial response [PR] and 1 complete response [CR]); 1 additional patient had an unconfirmed PR. All pts with a response received only 1 prior line of therapy. The duration of confirmed responses was 36 and 49 weeks (both ongoing). The disease control rate (PR or stable disease [SD] for ≥ 12 weeks) was 32% (6/19) in all pts and 50% (3/6) in pts with only 1 prior regimen. Four pts had SD, 9 had PD, and 3 were not evaluable for response. One pt with SD is ongoing at 60 weeks of treatment. Enrollment was stopped due to lack of responses in the first 15 pts evaluated; the 3 PRs occurred in the last 4 pts enrolled. Common treatment-related AEs included nausea and anemia (37% each). Common treatment-related grade ≥ 3 AEs included anemia (26%), thrombocytopenia (16%), and fatigue (11%). Conclusions: Rucaparib provided clinical benefit to pts with advanced PC and a BRCA mutation and demonstrated an acceptable safety profile. Less heavily pretreated pts derived durable benefit, suggesting that rucaparib may be an option earlier in the treatment course. These findings may inform future study designs in pts with advanced PC. Clinical trial information: NCT02042378.
Three-Dimensional Models of the Human Brain Development and Diseases
Authors: Mehdi Jorfi, Carla D'Avanzo, Doo Yeon Kim, Daniel Irimia
Journal: Advanced Healthcare Materials (2017)

Abstract Deciphering the human brain pathophysiology remains one of the greatest challenges of the 21 st century. Neurological disorders represent a significant proportion of diseases burden; however, the complexity of the brain physiology makes it challenging to model its diseases. Simple in vitro models have been very useful for precise measurements in controled conditions. However, existing models are limited in their ability to replicate complex interactions between various cells in the brain. Studying human brain requires sophisticated models to reconstitute the tangled architecture and functions of brain cells. Recently, advances in the development of three‐dimensional (3D) brain cell culture models have begun to recapitulate various aspects of the human brain physiology in vitro and replicate basic disease processes of Alzheimer's disease, amyotrophic lateral sclerosis, and microcephaly. In this review, we discuss the progress, advantages, limitations, and future directions of 3D cell culture systems for modeling the human brain development and diseases.
Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37–43
Authors: Filippo Alongi, Rosario Mazzola, Dario Aiello, Matteo Salgarello
Journal: European Urology (2016)
Diagnostic accuracy of interleukin 27 for tuberculous pleural effusion: two prospective studies and one meta-analysis
Authors: Wen Wang, Qiong Zhou, Kan Zhai, Yao Wang, Jing-Yuan Liu, Xiao-Juan Wang, Zhen Wang, Jian-Chu Zhang, Zhao-Hui Tong, Huan-Zhong Shi
Journal: Thorax (2017)

Background Accurate differentiating diagnosis is essential for choosing treatment for exudative pleural effusions. Objective To establish the diagnostic accuracy of interleukin 27 for tuberculous pleural effusion (TPE). Methods First, the concentrations of pleural interleukin 27, interferon-gamma and adenosine deaminase were compared between 51 patients with TPE and 103 with non-TPEs (Beijing cohort), and their diagnostic values were evaluated. These were further verified in another independent population (Wuhan cohort, n=120). In the second part of the study, we performed a meta-analysis. Results With a cut-off value of 591.4 ng/L in the Beijing cohort, the area under the curve, sensitivity, specificity, positive predictive value and negative predictive value of interleukin 27 to diagnose TPE were 0.983 (95% CI 0.947 to 0.997), 96.1% (86.5% to 99.5%), 99.0% (94.7% to 100%), 98.0 (89.4 to 99.9) and 98.1 (93.3 to 99.8), respectively. Excellent diagnostic accuracy of interleukin 27 was also found in the Wuhan cohort and was further confirmed in the meta-analysis. The diagnostic performance of interleukin 27 was comparable to that of interferon-gamma and was more accurate than that of adenosine deaminase. Since the post-test probability of a negative result was always &lt;0.1%, a negative test was considered to exclude TPE in all tuberculosis prevalence settings. Conclusions Interleukin 27 can be used to diagnose TPE in a high prevalence setting, and a negative result can also be reliably used to rule out TPE in all prevalence settings.
How to Use Blood Pressure Guidelines for Best Cognitive Outcomes
Authors: Rebecca F. Gottesman
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Transcriptome sequencing in pediatric acute lymphoblastic leukemia identifies fusion genes associated with distinct DNA methylation profiles
Authors: Yanara Marincevic-Zuniga, Johan Dahlberg, Sara Nilsson, Amanda Raine, Sara Nystedt, Carl Mårten Lindqvist, Eva C. Berglund, Jonas Abrahamsson, Lucia Cavelier, Erik Forestier, Mats Heyman, Gudmar Lönnerholm, Jessica Nordlund, Ann-Christine Syvänen
Journal: Journal of Hematology & Oncology (2017)

Structural chromosomal rearrangements that lead to expressed fusion genes are a hallmark of acute lymphoblastic leukemia (ALL). In this study, we performed transcriptome sequencing of 134 primary ALL patient samples to comprehensively detect fusion transcripts. We combined fusion gene detection with genome-wide DNA methylation analysis, gene expression profiling, and targeted sequencing to determine molecular signatures of emerging ALL subtypes. We identified 64 unique fusion events distributed among 80 individual patients, of which over 50% have not previously been reported in ALL. Although the majority of the fusion genes were found only in a single patient, we identified several recurrent fusion gene families defined by promiscuous fusion gene partners, such as ETV6, RUNX1, PAX5, and ZNF384, or recurrent fusion genes, such as DUX4-IGH. Our data show that patients harboring these fusion genes displayed characteristic genome-wide DNA methylation and gene expression signatures in addition to distinct patterns in single nucleotide variants and recurrent copy number alterations. Our study delineates the fusion gene landscape in pediatric ALL, including both known and novel fusion genes, and highlights fusion gene families with shared molecular etiologies, which may provide additional information for prognosis and therapeutic options in the future.